February 2026 Research Update

This group of studies points in the same direction: dermatomyositis monitoring is becoming more measurable using objective signals from blood, skin scoring tools, and day-to-day movement data. Some tools are close to routine clinical lab use, while others are still early and need broader validation. [1] [2] [3] [4] [5] [6] [7]

Several papers focused on blood tests that may help classify disease or track immune pathways. A flow cytometry test measured two interferon signals (type I and type II) by reading CD169 and CD274 on monocytes, and the authors described reproducible clinical lab implementation and potential use for monitoring response to interferon-targeted medicines across inflammatory diseases including juvenile dermatomyositis. [1]

Two studies addressed myositis-related autoantibody testing, which can affect how confidently a result matches a person s overall clinical picture. New enzyme-linked immunosorbent assays (ELISAs) for anti-SRP, anti-NXP2, and anti-SAE closely matched immunoprecipitation testing in 288 samples, supporting routine diagnostic use. [2] A separate evaluation found that the luciferase immunoprecipitation systems (LIPS) assay had near-perfect agreement with immunoprecipitation and performed better than line blot, where the chosen positivity threshold changed the balance of sensitivity and specificity. [4]

One exploratory study suggested an additional inflammation-related blood marker may reflect disease activity and lung involvement. Serum interleukin-38 (IL-38) was higher in adults with polymyositis/dermatomyositis than in controls, was highest in those with interstitial lung disease, and correlated with several inflammation and activity markers; combining IL-38 with lactate dehydrogenase improved diagnostic accuracy in that dataset. [3]

For skin-dominant dermatomyositis, two studies refined how skin activity scores can be interpreted and collected. In a large single-center analysis, specific Cutaneous Dermatomyositis Disease Area and Severity Index activity (CDASI-A) cutoffs aligned with physician global ratings and separated groups with different skin-related quality of life on Skindex-29. [5] In a small prospective study, simplified CDASI versions closely tracked the full CDASI, correlated with other skin assessments, and showed good inter-rater reliability and responsiveness. [6]

Two method-focused studies looked at measuring dermatomyositis beyond the clinic visit. Fitbit-based activity measures showed high wear compliance, strong test-retest reliability, and positive correlations over time with patient-reported and functional measures in idiopathic inflammatory myopathies including dermatomyositis. [7] Separately, a large Japanese study showed that using diagnosis codes alone in administrative claims data had limited accuracy, but combining codes with selected lab-testing and billing indicators improved identification of dermatomyositis/polymyositis for research and health-system tracking. [8]

For patients and caregivers, these studies mainly matter as progress in how dermatomyositis can be measured and followed, rather than as changes to treatment. Some tools (autoantibody ELISAs and interferon pathway testing by flow cytometry) were designed for clinical laboratories, while others (IL-38, simplified skin scores, and wearable activity measures) add options for capturing symptoms and function in a more standardized way but still need broader confirmation in different clinics and patient groups. Another key takeaway is that research based on insurance or hospital billing records can be more accurate when it uses multiple data signals instead of diagnosis codes alone, which can affect how trustworthy large database studies are. [1] [2] [3] [4] [5] [6] [7] [8]

Taken together, these papers show that lung involvement in dermatomyositis can range from stable disease to very rapid worsening, and that a few signals may help estimate risk. The most consistent signals were anti-MDA5 antibody status and changes over time, early respiratory symptoms at disease start, and how extensive the disease looked on chest scans. Several reports also highlighted that infections and complications during strong immune-suppressing treatment can be major drivers of serious illness and death. [9] [10] [11] [12] [13] [14] [15] [16] [17]

In one large real-world cohort that followed people with anti-MDA5-positive dermatomyositis and interstitial lung disease (ILD) who survived at least 6 months, two patterns of anti-MDA5 antibody change were seen: a faster drop to negative versus a slower decline. The faster-change group had fewer deaths and more people reached low disease activity and remission milestones over 12 to 36 months, and an early 3-month drop in anti-MDA5 levels helped predict which pattern a person would follow. [17]

Two retrospective cohort studies focused on early warning signs for worsening lung disease. One study of polymyositis/dermatomyositis-associated ILD found that a higher chest CT (scan) severity score, certain scan patterns, and anti-MDA5 status together separated people into low, intermediate, and high risk groups for acute or subacute worsening over 1 to 3 months. Another study in dermatomyositis found that when breathing symptoms were the first signs of the disease, respiratory outcomes were worse, and adding a specific skin finding on the elbows (elbow Gottron's sign) improved prediction of respiratory failure compared with symptoms alone. [12] [11]

Infection signals were common in anti-MDA5-positive dermatomyositis, especially in the setting of intensive immune-suppressing treatment. In a two-center cohort of 237 hospitalized patients, about one-third had cytomegalovirus (CMV) DNA detected in blood; overall 6-month death rates were similar whether CMV DNA was detected or not, but worse outcomes were reported within the CMV-positive group when rapid-progressing ILD, other infections, or higher CMV levels were present. In a separate small pilot series of six people treated with JAK inhibitors added to standard therapy, serious infections and complications were reported (including CMV infection), and half of the patients died within 6 months; higher ferritin and several immune signaling proteins in blood were higher before treatment in those who did not survive. [10] [13]

Several detailed case reports and small case series showed how varied anti-MDA5 dermatomyositis can be in real life, including lung disease that worsened very quickly despite multiple therapies, and other cases where lung imaging stabilized but long-term oxygen was still needed. One report described a medication-related lung complication (secondary pulmonary alveolar proteinosis) developing during tofacitinib, which improved quickly after stopping that drug. Another two-patient report, in people with anti-MDA5 antibody-positive lung disease, suggested that when ILD worsens after an initial remission, a lung biopsy technique (transbronchial lung cryobiopsy) may help separate ongoing inflammation from scarring, and rising anti-MDA5 levels occurred before deterioration in both cases. [9] [14] [15]

One additional case report described a person with advanced bladder cancer who developed anti-MDA5 antibody-positive ILD after receiving enfortumab vedotin plus pembrolizumab; despite strong immune-suppressing treatment, the ILD progressed quickly and the patient died. Because this is a single case, it cannot prove cause and effect, but it highlights that anti-MDA5-related lung disease can appear in complex medical situations. [18]

Finally, a multicenter Italian cohort comparing many kinds of interstitial lung disease found that autoimmune-related ILD (including dermatomyositis-related ILD) had longer survival on average than idiopathic pulmonary fibrosis, and lung function trends differed by diagnosis. In this study, the dermatomyositis-ILD subgroup showed an average improvement in forced vital capacity over time, while the idiopathic pulmonary fibrosis group showed an average decline. [16]

For patients and caregivers, this group of studies mainly adds context about why lung outcomes can differ so much from one person to another in dermatomyositis, especially when anti-MDA5 antibodies are present. Some tools under study (repeat anti-MDA5 blood levels, certain skin and symptom patterns at the start of disease, and scan-based scoring) are aimed at estimating near-term risk rather than changing what a diagnosis is. Uncertainty remains because several reports were small, some were single-center and retrospective, and multiple papers were case reports; this means the results may not apply the same way to every clinic or every patient.

Across these papers, researchers explored newer ways to control dermatomyositis by targeting specific parts of the immune system, rather than relying only on ongoing broad immune suppression. Evidence was early and based on very small, non-randomized reports, so it is still unclear how well these approaches work across different patients and how durable benefits are over many years. [19] [20]

In a small pediatric case series that included three children with dermatomyositis, a single infusion of autologous CD19 CAR T cells (an immune cell therapy designed to remove B cells) was followed by substantial improvement in disease activity, and patients were able to discontinue immunomodulator medicines after B cells returned, with a median follow-up of 16.5 months. Side effects were mostly mild, including low-grade cytokine release syndrome in six of eight patients and mild nervous system symptoms in one patient, and no severe infections were reported. [19]

A separate single-patient report discussed a 35-year-old woman whose dermatomyositis remained partly active despite long-term monthly intravenous immune globulin (IVIG) and who developed skin calcinosis. The authors proposed transitioning from IVIG to tofacitinib, a Janus kinase (JAK) inhibitor taken by mouth, but the report did not provide treatment outcomes from this switch. [20]

For patients and caregivers, these reports mainly serve as background on treatments being explored for dermatomyositis that aim for deeper immune reset (CAR T cells) or more targeted immune pathway blocking (JAK inhibitors). The CAR T cell experience described short-term to medium-term improvement with mostly mild side effects in a small group of children with severe, treatment-refractory autoimmune disease, but it does not yet tell us how this would compare with standard care or how long benefits last for dermatomyositis specifically. The tofacitinib paper highlights a potential rationale for switching from regular infusions to an oral medicine in an individual situation, but it provides no results, so effectiveness and safety for that scenario remain uncertain. [19] [20]

Across these reports, cancer and dermatomyositis (an inflammatory muscle and skin disease) appeared together often enough to highlight why doctors may look for an underlying tumor when dermatomyositis is new or atypical. The strongest pattern came from a small clinic series where a specific eye-area swelling was frequently seen in people who had an identified cancer, while individual case reports showed that cancer can be found even when some commonly discussed dermatomyositis-related cancer antibodies are negative. [21] [22]

In a retrospective case series of 10 adults with dermatomyositis and periorbital heliotrope edema with eyelid edema (prominent swelling and rash around the eyes), 9 had an imaging- and biopsy-confirmed cancer. Anti-TIF1-gamma antibodies were present in 8 people, and 7 of those 8 had cancer; the two anti-TIF1-gamma negative patients had other dermatomyositis antibodies (NXP-2 and MDA-5). [21]

One case report described a 21-year-old woman with anti-TIF1-gamma positive dermatomyositis who was found to have a solid pseudopapillary tumor of the pancreas. After surgical removal, her muscle enzymes normalized and skin symptoms improved, although major problems like weakness and swallowing difficulty persisted and she later died after severe complications, including infection. [23]

Another case report described a 71-year-old woman with dermatomyositis-like symptoms who was diagnosed with metastatic caecal (colon) adenocarcinoma, despite being negative for anti-TIF1-gamma and anti-NXP2 antibodies. She improved in strength and rash after intravenous immunoglobulin, and then started chemotherapy for the cancer. [22]

A postpartum case report described a 40-year-old woman diagnosed with dermatomyositis who presented with a malignant pleural effusion (cancer-related fluid around the lung) due to metastatic adenocarcinoma; testing suggested a gynecologic origin even though a primary tumor was not found on available imaging. Her dermatomyositis symptoms improved with immunosuppressive medicines, while the pleural effusion required drainage and pleurodesis, and chemotherapy was started for advanced cancer. [24]

For patients and caregivers, this set of studies mainly provides background about patterns doctors watch for: certain dermatomyositis features (like striking eyelid swelling) and some antibody results were often present in people later found to have cancer in a small series, and cancers were identified in several individual cases affecting different organs. Because most of the evidence here is exploratory (case reports and a small retrospective series), it cannot show how common these situations are or predict risk for any one person, and it also shows that cancer can be present even when some antibodies linked to cancer are negative.

Across these papers, dermatomyositis was described as beginning after specific triggers, especially cancer immune checkpoint medicines, and less commonly after a cholesterol-lowering statin or after COVID-19 infection. [25] [26] [27] Overall, reports suggested that skin and muscle symptoms often improved after clinicians treated the immune inflammation, but the evidence is mostly from case reports and individual cases, so it cannot predict what will happen for any one person. [25]

In a retrospective compilation of 49 published cases linked to anti-PD-1/PD-L1 cancer immunotherapy, most people developed new dermatomyositis after starting these medicines, and most stopped the immune therapy. [25] After treatments such as steroids, intravenous immunoglobulin (IVIG), and other immune-suppressing medicines, the majority had skin and muscle symptoms that improved or fully resolved. [25]

One case report described dermatomyositis developing after starting atorvastatin, first looking similar to statin-related muscle injury because muscle symptoms and a high muscle enzyme level were present. [26] Even after the statin was stopped, the muscle enzyme level stayed high and new skin changes appeared; a skin biopsy supported dermatomyositis, and symptoms gradually improved after prednisone and mycophenolate mofetil, with cancer screening reported as negative. [26]

Another case report linked dermatomyositis to a recent COVID-19 infection in a man with severe muscle weakness and swallowing trouble, and he had antinuclear matrix protein 2 antibody positivity. [27] His course included life-threatening complications, including gastrointestinal perforation requiring emergency surgery and a cardiopulmonary arrest, and he survived after high-dose IVIG and multidisciplinary hospital care. [27]

For patients and caregivers, this group of papers mainly provides context that dermatomyositis has been reported after certain immune-based cancer treatments and, more rarely, after other exposures like a statin or an infection like COVID-19. [25] [26] [27] The larger summary of immunotherapy-related cases suggests many people improved with immune-focused treatments, while single-patient reports show that presentations can be confusing at first (for example, resembling statin muscle injury) and that serious complications (such as swallowing problems and gastrointestinal perforation) can occur in some situations. [26] [27] Because much of the evidence comes from published case reports, it remains uncertain how common these trigger-related cases are and which individuals are most likely to have milder versus severe courses. [25]

Taken together, these papers highlight that dermatomyositis can sometimes show up with symptoms outside the typical skin and muscle picture, including significant swallowing problems and sudden, severe muscle injury that can be mistaken for other conditions. The strongest evidence in this set comes from one moderate-sized observational study of swallowing tests, while the rest are single-patient reports that illustrate what can happen but cannot show how often it occurs. [28] [29] [30] [31]

In a prospective cross-sectional study of 74 people with inflammatory muscle diseases, dermatomyositis stood out as the group most often showing moderate-to-severe oropharyngeal dysphagia (swallowing difficulty involving the throat). On an in-office swallowing camera test, dermatomyositis also differed from other myositis types in several throat-phase swallowing problems, and dermatomyositis was the only independent predictor of moderate-to-severe swallowing difficulty after adjusting for age and sex. [28]

Two separate case reports described anti-NXP-2 antibody-positive dermatomyositis presenting like rhabdomyolysis, with very high muscle enzyme levels and imaging that resembled drug-related muscle breakdown. In one patient there was no skin rash (dermatomyositis sine dermatitis) and the correct diagnosis was confirmed only after muscle biopsy and antibody testing, after the patient developed respiratory failure. [29]

A second anti-NXP-2 case report described a 56-year-old man whose dermatomyositis was complicated by rhabdomyolysis and included symptoms such as weakness and swallowing difficulty, with improvement and good reported quality of life at 6 months. Because this is a single patient, it shows what is possible rather than what is typical, and it does not establish that anti-NXP-2 antibodies generally cause rhabdomyolysis. [30]

Another single-patient report described delayed recognition of dermatomyositis in a 59-year-old woman with skin of color who presented with progressive weakness and cardiac symptoms; blood tests later supported dermatomyositis and she improved after immunotherapy, then went to rehabilitation. This case underlines that dermatomyositis may sometimes be evaluated through the lens of other problems (including heart-related symptoms), which can slow clear identification of the underlying disease. [31]

For patients and caregivers, this set of studies mainly serves as context for why dermatomyositis can sometimes be hard to recognize when swallowing problems, breathing problems, severe muscle injury, or heart symptoms are prominent. The swallowing study suggests these throat-swallowing issues may be especially relevant in dermatomyositis compared with some other inflammatory muscle diseases, while the case reports show uncommon but serious presentations (including rhabdomyolysis-like episodes) that required specialized testing to clarify. What remains uncertain is how often these unusual patterns happen, which people are most at risk, and whether specific antibodies reliably predict these complications, because most of the evidence here comes from single cases rather than larger, long-term studies. [28] [29] [30] [31]

Across these studies, unusual complications and overlaps were reported, but most evidence came from small case-based research. The overall message is that dermatomyositis can coexist with other immune-related conditions and may show unexpected antibody patterns, while some lab markers seen on muscle biopsy may help describe disease biology but are not reliable as stand-alone diagnostic separators. [32] [33] [34] [35]

One case report described a 41-year-old man with dermatomyositis who had anti-SAE antibodies and was also diagnosed with Rosai-Dorfman disease after imaging showed multiple painless enlarged lymph nodes and a lymph node biopsy confirmed the diagnosis. The authors noted this as the first reported dermatomyositis case with Rosai-Dorfman disease and suggested there may be shared immune-related mechanisms, but this cannot be proven from a single patient. [32]

A separate pediatric case report described a young child with juvenile dermatomyositis who had multiple muscle-specific autoantibodies detected on blood testing, although details were not available in the provided materials. Even without full information, it highlights that antibody testing can sometimes produce unexpected patterns that may complicate interpretation. [33]

In an observational muscle-biopsy study focused on immune-mediated necrotizing myopathy and other muscle diseases, staining for phospho-MLKL (a marker related to a type of programmed cell death) was common across multiple conditions. Dermatomyositis showed a different spatial pattern (staining around microinfarcts but not inside them), but because the marker was also frequently present in other muscle diseases, the authors concluded it has limited usefulness as a diagnostic biomarker by itself. [34]

A retrospective case series followed seven people who had juvenile dermatomyositis in childhood and later met criteria for spondyloarthritis, most often a peripheral form with arthritis and tendon/ligament insertion pain. The report noted MRI-confirmed myositis during the juvenile dermatomyositis phase and described later imaging and clinical features typical of spondyloarthritis, with most patients improving on standard spondyloarthritis treatments; because the series was small and retrospective, it cannot show how common this overlap is. [35]

For patients, this theme is mainly background information explaining why dermatomyositis care sometimes involves looking beyond muscle and skin and why test results can be complex. Rare overlaps (like Rosai-Dorfman disease) and unusual antibody profiles are reported but are based on individual cases, so they do not indicate typical outcomes. The biopsy-marker study is relevant to understanding that some tissue markers may reflect underlying biology yet still not be specific enough to clearly label a myositis subtype on their own, and the juvenile series raises the possibility of later inflammatory joint disease in a small group, with major uncertainty about frequency and risk factors. [32] [33] [34] [35]

Across multiple exploratory studies, dermatomyositis biology repeatedly showed a pattern of immune pathways that look like an amplified antiviral response. Signals linked to type I interferon (a family of immune messenger proteins) appeared in blood, plasma, and muscle, and some studies connected these signals to muscle enzyme levels, inflammation markers, and symptom-related questionnaires. These studies help map pathways, but they do not yet show which signals directly cause specific symptoms in every patient. [36] [37] [38] [39] [40] [41]

In one small adult dermatomyositis study, a blood protein called OAS3 was higher in dermatomyositis than in healthy controls, and higher OAS3 levels went along with higher creatine kinase (a muscle enzyme often used as a sign of muscle irritation or injury). The authors placed OAS3 in a larger type I interferon signaling network, but the study did not test whether changing OAS3 changes disease. [36]

In juvenile dermatomyositis, blood testing showed lower tryptophan and serotonin and higher kynurenine-pathway metabolites compared with healthy controls, a pattern the authors linked to interferon-driven activation of an enzyme called IDO1. Several of these metabolites moved in the same direction as inflammation and disease activity measures, and some also tracked with anxiety or depression questionnaire scores in this group. Lab experiments showed that interferon could trigger IDO changes in immune cells, and this was reduced by interferon- or signaling-blocking drugs in the test system, which supports the proposed pathway but does not prove what happens in every child in real-world care. [37]

Other work broadened the picture of immune activation beyond interferon alone. In a mixed group of idiopathic inflammatory myopathy patients (including dermatomyositis), blood cells and serum showed higher levels of AIM2 inflammasome pathway markers and inflammatory cytokines, consistent with a cell-death and inflammation process sometimes called pyroptosis. This supports the idea that multiple immune "alarm" systems may be turned on at the same time. [39]

Two additional studies suggest that interferon-linked patterns are not limited to classic dermatomyositis. A pediatric overlap group with features of both juvenile myositis and juvenile systemic sclerosis showed a strong type I interferon gene signature in blood, but samples split into subgroups that resembled either juvenile dermatomyositis or juvenile systemic sclerosis, highlighting biological heterogeneity. Separately, a computational analysis comparing rheumatoid arthritis and dermatomyositis datasets identified shared inflammatory pathways and immune-cell shifts, but these results are based on public data and need lab confirmation. [40] [41]

One lab study identified a type I interferon-inducible long noncoding RNA called USP30-AS1 that helped stabilize messenger RNAs for innate immune sensors and certain interferon-stimulated genes in human macrophage models. Disease datasets (including dermatomyositis) showed higher USP30-AS1 levels that rose along with interferon pathway activity, suggesting one possible way interferon responses could stay turned on longer than normal. This was cell-model research and did not test dermatomyositis tissues directly in patients. [38]

For patients and caregivers, these studies mainly add background about why dermatomyositis can behave like an immune system stuck in an antiviral mode. Some blood patterns (like OAS3 or tryptophan breakdown products) matched measures of inflammation or muscle irritation in small groups, but it remains uncertain whether these markers can reliably track day-to-day disease activity for individuals, or whether they drive symptoms versus reflecting downstream immune activation. The juvenile data also raise the possibility that immune-metabolism links may relate to both physical inflammation and mental health questionnaires in some children, but this needs larger, more diverse, and longer-term studies to confirm how consistent and clinically meaningful the links are. [36] [37]

A second set of studies focused on how autoantibodies (immune proteins that recognize the body) could contribute to dermatomyositis tissue changes in specific antibody-defined subtypes. Together, they describe several non-identical mechanisms: precise targeting of the MDA5 protein by certain B cells, complement-driven immune injury in the liver in anti-MDA5 disease models, and evidence that antibodies may access the inside of cells and alter gene programs in anti-Mi-2 and anti-PM/Scl myopathies. A separate clinical study suggested that small blood vessel changes may improve on a different timeline than symptoms in anti-Mi-2 dermatomyositis. [42] [43] [44] [45]

In an in vitro study using B cells from three people with anti-MDA5 dermatomyositis, researchers rebuilt patient antibodies and found two that bound strongly to the helicase parts of the MDA5 protein, each recognizing a different target spot. The work also mapped a linear target region that matched what was seen in patient blood testing, supporting the idea that some patients develop focused, "on-target" B cell responses rather than a broad, random reaction. This was a small laboratory study and did not measure clinical outcomes. [42]

A mouse model plus human autopsy analysis suggested a pathway for anti-MDA5 related liver injury involving complement and macrophages (a type of immune cell). In human autopsy livers, both CD80-positive (often described as M1-like) and CD206-positive (often described as M2-like) macrophages were present, and in transgenic mice given anti-MDA5 antibodies, liver injury came with more CD206-positive macrophages. In the model, removing complement factor C3 markedly reduced liver injury, which supports an antibody-complement-macrophage interaction in this setting, while leaving uncertainty about how early this process begins in living patients. [43]

A large multicenter study of muscle and skin samples proposed that in some intracellular-target autoimmune diseases, patient immunoglobulin G (IgG) can access the inside of cells and trigger disease-specific gene programs. Anti-Mi-2 dermatomyositis showed IgG in cell nuclei and a distinct muscle gene signature that could be recreated in cultured human muscle cells exposed to patient IgG, while anti-PM/Scl disease showed different localization (nucleoli) and a different immune environment. The authors noted important limitations, including that their cell experiments used a method that bypasses normal antibody entry routes, so the exact in-body mechanism still needs proof. [44]

One clinical study in anti-Mi-2 dermatomyositis used artificial intelligence assisted capillaroscopy (a close look at small blood vessels) and reported that symptom remission and microvascular improvement did not occur in lockstep over time. This suggests that blood vessel changes may persist even when a person feels better, although the summary does not include sample size or detailed timing, and the reasons for the delay are not yet clear. [45]

For patients, these studies reinforce that dermatomyositis is not one single biological process and that antibody-defined subtypes can involve different tissue pathways (for example, anti-MDA5 focused antibody targets and complement-linked liver injury mechanisms, versus anti-Mi-2 patterns that may involve antibodies reaching the inside of cells). Much of this evidence is lab-based, model-based, or focused on specialized tissue testing, so it mainly helps explain disease mechanisms rather than changing care right now. Key uncertainties include how often these pathways operate in everyday clinical situations, what triggers them, and which signals best reflect ongoing tissue injury when symptoms improve. [43] [44]